Vincent W. Coljee
Corporate Officer/Principal chez Harvard University
Profil
Vincent W.
Coljee was the founder of Excelimmune, Inc. which was founded in 2006, where he held the title of Chief Scientific Officer from 2010 to 2013.
Currently, he holds the title of Principal at Harvard University.
In the past, he held the title of Principal at Symphogen A.
Postes actifs de Vincent W. Coljee
| Sociétés | Poste | Début |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Anciens postes connus de Vincent W. Coljee
| Sociétés | Poste | Fin |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Excelimmune, Inc.
 Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Excelimmune, Inc.
Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Commercial Services |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
